CoLucid Pharmaceuticals Company Profile (NASDAQ:CLCD)

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals logoCoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLCD
  • CUSIP:
Key Metrics:
  • Previous Close: $46.53
  • 50 Day Moving Average: $44.610
  • 200 Day Moving Average: $33.786
  • 52-Week Range: $5.26 - $46.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -18.39
  • P/E Growth: 0.000
  • Market Cap: $895.42M
  • Outstanding Shares: 19,246,000
  • Beta: 1.51
Profitability:
  • Return on Equity: -81.71%
  • Return on Assets: -72.06%
Debt:
  • Current Ratio: 11.31%
  • Quick Ratio: 11.30%
Additional Links:
Companies Related to CoLucid Pharmaceuticals:

Analyst Ratings

Consensus Ratings for CoLucid Pharmaceuticals (NASDAQ:CLCD) (?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $48.10 (3.39% upside)

Analysts' Ratings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Show:
DateFirmActionRatingPrice TargetDetails
1/23/2017Barclays PLCDowngradeOverweight -> Equal Weight$45.00View Rating Details
1/18/2017BTIG ResearchSet Price TargetBuy$52.00View Rating Details
1/18/2017William BlairDowngradeOutperform -> Market PerformView Rating Details
1/18/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$49.00 -> $46.50View Rating Details
10/24/2016Stifel NicolausBoost Price TargetBuy$30.00 -> $40.00View Rating Details
9/19/2016Ladenburg Thalmann Financial ServicesSet Price TargetBuy$57.00View Rating Details
(Data available from 3/1/2015 forward)

Earnings

Earnings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
8/10/2016Q2($0.84)($1.06)ViewN/AView Earnings Details
5/11/2016Q1($0.73)($0.85)ViewN/AView Earnings Details
11/10/2015Q3($0.63)($0.59)ViewN/AView Earnings Details
8/12/2015($0.35)($1.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Current Year EPS Consensus Estimate: $-3.540 EPS
Next Year EPS Consensus Estimate: $-2.530 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.92)($0.92)($0.92)
Q4 20161($0.85)($0.85)($0.85)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 64.17%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/5/2017Linda C HoganInsiderSell2,580$35.18$90,764.40View SEC Filing  
1/5/2017Thomas P MathersCEOSell1,502$34.78$52,239.56View SEC Filing  
1/3/2017Bernice KucaInsiderSell772$36.25$27,985.00View SEC Filing  
1/3/2017Matthew D DallasCFOSell1,473$36.25$53,396.25View SEC Filing  
12/5/2016Linda C HoganInsiderSell2,583$37.77$97,559.91View SEC Filing  
12/5/2016Thomas P. MathersCEOSell1,502$38.75$58,202.50View SEC Filing  
12/1/2016Bernice KucaInsiderSell772$35.22$27,189.84View SEC Filing  
12/1/2016Matthew D. DallasCFOSell1,473$35.17$51,805.41View SEC Filing  
11/7/2016Linda C HoganInsiderSell1,862$28.56$53,178.72View SEC Filing  
11/7/2016Thomas P MathersCEOSell1,502$28.57$42,912.14View SEC Filing  
11/1/2016Linda C HoganInsiderSell719$30.00$21,570.00View SEC Filing  
10/5/2016Linda C HoganInsiderSell2,581$37.22$96,064.82View SEC Filing  
10/5/2016Thomas P MathersCEOSell1,502$37.08$55,694.16View SEC Filing  
9/14/2016Thomas P MathersCEOSell6,000$23.32$139,920.00View SEC Filing  
9/9/2016A/S NovoMajor ShareholderBuy100,000$20.00$2,000,000.00View SEC Filing  
9/7/2016Thomas P MathersCEOSell6,502$21.72$141,223.44View SEC Filing  
9/6/2016Linda C HoganInsiderSell48,736$19.87$968,384.32View SEC Filing  
8/31/2016Raymond SkwierczynskiInsiderSell150$10.86$1,629.00View SEC Filing  
8/19/2016Raymond SkwierczynskiInsiderSell508$8.41$4,272.28View SEC Filing  
8/10/2016Raymond SkwierczynskiInsiderSell508$8.30$4,216.40View SEC Filing  
8/5/2016Thomas P MathersCEOSell1,502$8.31$12,481.62View SEC Filing  
8/3/2016Domain Partners Vi, L.P.Major ShareholderSell153,028$8.45$1,293,086.60View SEC Filing  
7/29/2016Raymond SkwierczynskiInsiderSell508$9.09$4,617.72View SEC Filing  
7/20/2016Raymond SkwierczynskiInsiderSell508$8.97$4,556.76View SEC Filing  
7/11/2016Raymond SkwierczynskiInsiderSell508$9.10$4,622.80View SEC Filing  
6/30/2016Raymond SkwierczynskiInsiderSell516$7.01$3,617.16View SEC Filing  
6/20/2016Raymond SkwierczynskiInsiderSell1,008$6.80$6,854.40View SEC Filing  
6/6/2016Thomas P MathersCEOSell1,502$7.25$10,889.50View SEC Filing  
4/28/2016Vi Associates L.P. DpMajor ShareholderSell235$6.96$1,635.60View SEC Filing  
8/25/2015Thomas P MathersCEOBuy7,500$7.10$53,250.00View SEC Filing  
5/11/2015A/S NovoMajor ShareholderBuy1,300,000$10.00$13,000,000.00View SEC Filing  
5/11/2015Arthur M PappasDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CoLucid Pharmaceuticals (NASDAQ:CLCD)
DateHeadline
News IconLilly Completes Acquisition (NASDAQ:CLCD)
www.insideindianabusiness.com - March 1 at 12:07 PM
News IconVolatility Watch on Shares of CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Providence Standard (NASDAQ:CLCD)
providencestandard.com - February 28 at 4:35 PM
News IconInvestor Center: Technicals in View for CoLucid Pharmaceuticals Inc (CLCD) - Midway Monitor (NASDAQ:CLCD)
midwaymonitor.com - February 28 at 7:20 AM
News IconStock Update for CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Midway Monitor (NASDAQ:CLCD)
midwaymonitor.com - February 24 at 4:33 PM
News IconNASDAQ:CLCD Investor News: Lawsuit against Buyout of CoLucid Pharmaceuticals Inc filed (NASDAQ:CLCD)
www.groundreport.com - February 23 at 2:29 AM
News IconSell-side Taking Aim at Shares of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - Aiken Advocate (NASDAQ:CLCD)
aikenadvocate.com - February 22 at 11:52 AM
News IconIndicators in Focus on CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - BVN (NASDAQ:CLCD)
bvnewsjournal.com - February 21 at 3:29 PM
News IconCoLucid Pharmaceuticals Inc CLCD Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:CLCD)
www.bioportfolio.com - February 18 at 4:10 PM
sbwire.com logoLawsuit Filed for Investors in Shares of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) in Effort to Halt the Takeover by Eli Lilly and Company (NASDAQ:CLCD)
www.sbwire.com - February 13 at 9:59 PM
News IconLawsuit Filed for Investors in Shares of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) in Effort to Halt the Takeover by ... - Satellite PR News (press release) (NASDAQ:CLCD)
www.satprnews.com - February 13 at 4:59 PM
News IconIndicator Level Review for Colucid Pharmaceuticals Inc. (CLCD) - Piedmont Register (NASDAQ:CLCD)
piedmontregister.com - February 10 at 9:36 PM
News IconInvestor Hub: Checking on the Numbers for CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Sherwood Daily (NASDAQ:CLCD)
sherwooddaily.com - February 10 at 4:35 PM
News IconAcquisition of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) under Investigation for Investors (NASDAQ:CLCD)
www.groundreport.com - February 2 at 4:40 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders (NASDAQ:CLCD)
finance.yahoo.com - February 2 at 4:39 PM
News IconInvestigation Initiated By Levi & Korsinsky Over The Sale Of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) (NASDAQ:CLCD)
randolphguide.com - February 1 at 4:36 PM
uk.finance.yahoo.com logoBragar Eagel & Squire, P.C. Is Investigating the Board … (NASDAQ:CLCD)
uk.finance.yahoo.com - January 31 at 9:47 PM
finance.yahoo.com logoBragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. (CLCD) on Behalf of Stockholders and Encourages Investors to Contact the Firm (NASDAQ:CLCD)
finance.yahoo.com - January 31 at 9:47 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD (NASDAQ:CLCD)
finance.yahoo.com - January 31 at 4:45 PM
businesswire.com logoINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional ... (NASDAQ:CLCD)
www.businesswire.com - January 30 at 10:14 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information (NASDAQ:CLCD)
finance.yahoo.com - January 30 at 10:14 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD (NASDAQ:CLCD)
finance.yahoo.com - January 27 at 5:44 PM
News IconEarnings in Full Force, Analysts Take Aim at CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - Wall Street Beacon (NASDAQ:CLCD)
wsbeacon.com - January 26 at 10:27 PM
4-traders.com logoRobbins Arroyo LLP: Acquisition of CoLucid Pharmaceuticals, Inc. CLCD by Eli Lilly and Company LLY May Not Be in Shareholders' Best Interests (NASDAQ:CLCD)
www.4-traders.com - January 26 at 5:25 PM
News IconWhat are Analysts Expecting for CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Earnings? - Aiken Advocate (NASDAQ:CLCD)
aikenadvocate.com - January 26 at 3:29 AM
News IconAre Firms & Funds Cutting Back Their Holdings in CoLucid ... - Wall Street Beacon (NASDAQ:CLCD)
wsbeacon.com - January 26 at 3:29 AM
4-traders.com logoNASDAQ:CLCD Investor Notice: Investigation of Takeover of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD)
www.4-traders.com - January 24 at 4:54 PM
News IconRecent Analyst Updates on: CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) (NASDAQ:CLCD)
vgtoday.net - January 24 at 4:54 PM
News IconCoLucid Pharmaceuticals Inc (CLCD) is Downgraded by Barclays to " Equal Weight" (NASDAQ:CLCD)
baddgoddess.com - January 24 at 4:54 PM
News IconPiper Jaffray Cos. Lowers CoLucid Pharmaceuticals Inc. (CLCD) to Neutral (NASDAQ:CLCD)
larampadinapoli.com - January 24 at 2:40 AM
News IconWilliam Blair Lowers CoLucid Pharmaceuticals Inc. (CLCD) to Market Perform (NASDAQ:CLCD)
perspectivabetica.com - January 24 at 2:40 AM
businesswire.com logoSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional ... (NASDAQ:CLCD)
www.businesswire.com - January 23 at 4:37 PM
News IconThe BTIG Research Initiates Coverage on CoLucid Pharmaceuticals Inc. (CLCD) (NASDAQ:CLCD)
flapship.com - January 23 at 4:37 PM
marketexclusive.com logoAnalyst Downgrades – CoLucid Pharmaceuticals (NASDAQ:CLCD) Stock Gets Downgraded By Barclays PLC from ... - Market Exclusive (NASDAQ:CLCD)
marketexclusive.com - January 23 at 4:37 PM
News IconCoLucid Pharmaceuticals Inc (CLCD) is Downgraded by Barclays to ” Equal Weight” - Highland Mirror (NASDAQ:CLCD)
www.highlandmirror.com - January 23 at 4:37 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information (NASDAQ:CLCD)
finance.yahoo.com - January 23 at 4:37 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information (NASDAQ:CLCD)
finance.yahoo.com - January 23 at 4:37 PM
prnewswire.com logoSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid ... - PR Newswire (press release) (NASDAQ:CLCD)
www.prnewswire.com - January 21 at 9:26 PM
prnewswire.com logoCOLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals ... - PR Newswire (press release) (NASDAQ:CLCD)
www.prnewswire.com - January 21 at 9:26 PM
News IconCoLucid Pharmaceuticals Inc CLCD Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CLCD)
www.bioportfolio.com - January 20 at 5:30 PM
finance.yahoo.com logoCOLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals, Inc. (CLCD) Over the Proposed Sale of the Company to Eli Lilly and Company (NASDAQ:CLCD)
finance.yahoo.com - January 20 at 5:30 PM
4-traders.com logoCOLUCID PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation Of Buyout (NASDAQ:CLCD)
www.4-traders.com - January 20 at 3:36 AM
News IconAre Institutions Trimming Down Their Positions In CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Wall Street Beacon (NASDAQ:CLCD)
wsbeacon.com - January 19 at 10:35 PM
prnewswire.com logoCoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in ... - PR Newswire (press release) (NASDAQ:CLCD)
www.prnewswire.com - January 19 at 10:35 PM
streetinsider.com logoEli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M - StreetInsider.com (NASDAQ:CLCD)
www.streetinsider.com - January 19 at 10:34 PM
News IconLilly to buy migraine drug developer CoLucid for $960m (NASDAQ:CLCD)
prensariotiretail.com - January 19 at 5:33 PM
News IconJazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers (NASDAQ:CLCD)
lasignare.com - January 19 at 5:33 PM
rttnews.com logoCoLucid Pharmaceuticals Inc. (CLCD) Leaped To A New High On Merger News (NASDAQ:CLCD)
www.rttnews.com - January 19 at 5:33 PM
News IconNext Weeks Broker Price Targets For CoLucid Pharmaceuticals, Inc. (CLCD) (NASDAQ:CLCD)
diy-home-garden.com - January 19 at 5:33 PM
finance.yahoo.com logoRobbins Arroyo LLP: Acquisition of CoLucid Pharmaceuticals, Inc. (CLCD) by Eli Lilly and Company (LLY) May Not Be in Shareholders' Best Interests (NASDAQ:CLCD)
finance.yahoo.com - January 19 at 5:33 PM
News IconLilly reclaims phase III migraine therapy in $960M buyout of Colucid (NASDAQ:CLCD)
www.bioworld.com - January 18 at 9:40 PM

Social

What is CoLucid Pharmaceuticals' stock symbol?

CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD."

Where is CoLucid Pharmaceuticals' stock going? Where will CoLucid Pharmaceuticals' stock price be in 2017?

6 analysts have issued 12-month target prices for CoLucid Pharmaceuticals' shares. Their predictions range from $40.00 to $57.00. On average, they expect CoLucid Pharmaceuticals' share price to reach $48.10 in the next year.

When will CoLucid Pharmaceuticals announce their earnings?

CoLucid Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 9th 2016.

What are analysts saying about CoLucid Pharmaceuticals stock?

Here are some recent quotes from research analysts about CoLucid Pharmaceuticals stock:

  • Piper Jaffray Companies analysts commented, "We see this announcement as resulting from CoLucid's clean design and execution of its Phase III program for oral lasmiditan, and expect the second Phase III SPARTAN trial to read out on schedule in 3Q17. On the GLADIATOR open-label study, we believe that retention rates remain at >70% and that Lilly has likely performed thorough diligence on ongoing safety, efficacy, and compliance in the program. Therefore we see relatively low risk to new information arising in the near-term which threatens completion of this transaction. Overall, the bid confirms our long-held thesis around clinical value of a new acute migraine treatment that provides advantages over standard-of-care triptans on CV safety as well as efficacy for some patients. At this time, we are reducing our rating for CLCD to Neutral." (1/18/2017)
  • According to Zacks Investment Research, "CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company's product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts. " (1/10/2017)

Who owns CoLucid Pharmaceuticals stock?

CoLucid Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Novo A S (16.40%), FMR LLC (6.85%), Perceptive Advisors LLC (3.33%), Marshall Wace LLP (2.52%), Vivo Capital LLC (1.17%) and J. Goldman & Co LP (0.67%). Company insiders that own CoLucid Pharmaceuticals stock include A/S Novo, Arthur M Pappas, Bernice Kuca, Domain Partners Vi, LP, Linda C Hogan, Matthew D Dallas, Raymond Skwierczynski, Thomas P Mathers and Vi Associates LP Dp.

Who sold CoLucid Pharmaceuticals stock? Who is selling CoLucid Pharmaceuticals stock?

CoLucid Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., Renaissance Technologies LLC and Artal Group S.A.. Company insiders that have sold CoLucid Pharmaceuticals stock in the last year include Bernice Kuca, Domain Partners Vi, LP, Linda C Hogan, Matthew D Dallas, Raymond Skwierczynski, Thomas P Mathers and Vi Associates LP Dp.

Who bought CoLucid Pharmaceuticals stock? Who is buying CoLucid Pharmaceuticals stock?

CoLucid Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Marshall Wace LLP, Bogle Investment Management L P DE, J. Goldman & Co LP, Russell Investments Group Ltd., Allianz Asset Management AG and State Street Corp. Company insiders that have bought CoLucid Pharmaceuticals stock in the last two years include A/S Novo, Arthur M Pappas and Thomas P Mathers.

How do I buy CoLucid Pharmaceuticals stock?

Shares of CoLucid Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CoLucid Pharmaceuticals stock cost?

One share of CoLucid Pharmaceuticals stock can currently be purchased for approximately $46.53.

CoLucid Pharmaceuticals (NASDAQ:CLCD) Chart for Wednesday, March, 1, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)

Earnings History Chart

Earnings by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)

Dividend History Chart

Dividend Payments by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)

Last Updated on 3/1/2017 by MarketBeat.com Staff